|
業務類別
|
Biotechnology |
|
業務概覽
|
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape. |
| 公司地址
| 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 781 317-0290 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kailera.com |
| 員工數量
| 145 |
| Mr. Ronald C. Renaud, Jr,M.B.A. |
Director, President and Chief Executive Officer |
-- |
27/03/2026 |
| Mr. Paul Burgess, J.D.,M.S. |
Chief Operating Officer and Chief Business Officer |
-- |
27/03/2026 |
| Mr. Douglas W. Pagan |
Chief Financial Officer |
-- |
27/03/2026 |
| Ms. Paula Cloghessy |
Chief People Officer |
-- |
13/04/2026 |
| Mr. Scott M. Akamine, J.D. |
Chief Legal Officer and Secretary |
-- |
27/03/2026 |
| Ms. Jamie Coleman |
Chief Commercial Officer |
-- |
13/04/2026 |
| Mr. Scott Wasserman |
Chief Medical Officer |
-- |
27/03/2026 |
|
|
| Dr. Martin W. Mackay, PhD |
Director |
27/03/2026 |
| Mr. Ronald C. Renaud, Jr,M.B.A. |
Director, President and Chief Executive Officer |
27/03/2026 |
| Dr. John F. Milligan, PhD |
Chairman of the Board |
13/04/2026 |
| Dr. Adam M. Koppel, M.D.,PhD |
Director |
27/03/2026 |
| Mr. Andrew T. Kaplan |
Director |
27/03/2026 |
| Mr. Franklin K. Clyburn, Jr |
Director |
27/03/2026 |
| Mr. Christopher Hite |
Director |
27/03/2026 |
| Mr. Michael Gladstone |
Director |
13/04/2026 |
| Dr. Yuting Liu, PhD |
Director |
27/03/2026 |
| Dr. Amir Zamani, M.D. |
Director |
13/04/2026 |
|
|
|
|
